BASF ups Pronova bid


BASF has increased its offer for Norwegian firm Pronova BioPharma, which specialises in omega-3 fatty acids, from €664 million (£530 million) to €684 million in an attempt to win over reluctant shareholders.

The company made its initial offer in November 2012 with the support of the board and shareholders representing 60% of the company, including private equity fund Herkules, which owns a 50% stake.

Since then, the bid has been accepted by investors owning 70% of the issued shares. The new offer lasts until 18 January and will not be extended, BASF says.

Pronova makes active pharmaceutical ingredients based on omega-3 fatty acids that are used to treat cardiovascular conditions. It also makes dietary supplements. It employs 300 people and makes annual sales of about NOK1.7 billion (£180 million).

BASF strengthened its position in this growing market in May 2012 when it bought UK firm Equateq.


Related Content

BASF bids €664m for omega-3 company

22 November 2012 Business

news image

Pronova BioPharma makes pharmaceutical ingredients as well as nutritional supplements based in omega-3 fatty acids

BASF to cut 260 jobs in nutrition and health

1 May 2014 Business

news image

Firm to sell Norwegian site and shift focus towards Asia

Most Read

Enthralled by evaporation

20 February 2015 Organic Matter

news image

A giant rotary evaporator is a mesmerising thing, says Chemjobber, but the plant requires a different approach

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Nanoporous methane storage – an impossible target?

18 February 2015 Research

news image

Identifying performance limits for nanoporous materials highlights that current methane storage goals might be unrealistic

Enthralled by evaporation

20 February 2015 Organic Matter

news image

A giant rotary evaporator is a mesmerising thing, says Chemjobber, but the plant requires a different approach